Cannabinol (CBN)
OTHER NAME(S): Cannabinol, CBN, Cannabinol
Overview
Cannabinol is a chemical found in the Cannabis sativa plant. Research on this chemical is limited and its effects are unclear.
Some early research suggests that cannabinol might affect the immune system and reduce pain.
People sometimes use cannabinol for insomnia and other conditions, but there is no good scientific evidence to support these uses.
Uses
We currently have no information for Cannabinol (CBN) overview.
Side Effects
When applied to the skin: There isn't enough reliable information to know if cannabinol is safe or what the side effects might be.
When taken by mouth: Cannabinol is POSSIBLY SAFE for adults when it is taken by mouth at a dose of up to 20 mg daily for up to 7 days. It might cause side effects such as altered taste, headache, and sleepiness. There isn't enough reliable information to know if cannabinol is safe when used in larger doses or for more than 7 days.
Precautions
When applied to the skin: There isn't enough reliable information to know if cannabinol is safe or what the side effects might be.
When taken by mouth: Cannabinol is POSSIBLY SAFE for adults when it is taken by mouth at a dose of up to 20 mg daily for up to 7 days. It might cause side effects such as altered taste, headache, and sleepiness. There isn't enough reliable information to know if cannabinol is safe when used in larger doses or for more than 7 days.
Pregnancy and breast-feeding: There isn't enough reliable information to know if cannabinol is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.
Interactions
Moderate Interaction
Be cautious with this combination
- Medications changed by the liver (Cytochrome P450 1A1 (CYP1A1) substrates) interacts with Cannabinol (CBN)Some medications are changed and broken down by the liver. Cannabinol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
- Medications that decrease breakdown of other medications by the liver (Cytochrome P450 2C9 (CYP2C9) inhibitors) interacts with Cannabinol (CBN)Cannabinol is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down cannabinol. This could change the effects and side effects of cannabinol.
- Medications that decrease the breakdown of other medications in the liver (Cytochrome P450 3A4 (CYP3A4) inhibitors) interacts with Cannabinol (CBN)Cannabinol is changed and broken down by the liver. Some drugs decrease how quickly the liver changes and breaks down cannabinol. This could change the effects and side effects of cannabinol.
- Medications changed by the liver (Cytochrome P450 2B6 (CYP2B6) substrates) interacts with Cannabinol (CBN)Some medications are changed and broken down by the liver. Cannabinol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
- Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with Cannabinol (CBN)Some medications are changed and broken down by the liver. Cannabinol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
- Medications changed by the liver (Cytochrome P450 2E1 (CYP2E1) substrates) interacts with Cannabinol (CBN)Some medications are changed and broken down by the liver. Cannabinol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Dosing
There isn't enough reliable information to know what an appropriate dose of cannabinol might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.
References
- Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 2010;79(11):1691-8.
- De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479-94.
- Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Arch Oral Biol. 2019;104:33-39.
- Farrimond JA, Whalley BJ, Williams CM. Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. Psychopharmacology (Berl). 2012;223(1):117-29.
- Herring AC, Kaminski NE. Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J Pharmacol Exp Ther. 1999;291(3):1156-63.
- Herring AC, Koh WS, Kaminski NE. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem Pharmacol. 1998;55(7):1013-23.
- Jan TR, Kaminski NE. Role of mitogen-activated protein kinases in the differential regulation of interleukin-2 by cannabinol. J Leukoc Biol. 2001;69(5):841-9.
- Johansson E, Ohlsson A, Lindgren JE, Agurell S, Gillespie H, Hollister LE. Single-dose kinetics of deuterium-labelled cannabinol in man after intravenous administration and smoking. Biomed Environ Mass Spectrom. 1987;14(9):495-9.
- Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 2007;80(15):1415-9.
- Kroner GM, Johnson-Davis KL, Doyle K, McMillin GA. Cannabinol (CBN) Cross-Reacts with Two Urine Immunoassays Designed to Detect Tetrahydrocannabinol (THC) Metabolite. J Appl Lab Med. 2020;5(3):569-574.
- Czégény Z, Nagy G, Babinszki B, et al. CBD, a precursor of THC in e-cigarettes. Sci Rep 2021;11(1):8951.
- Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metab Dispos 2021;49(12):1070-1080.
- Stahl V, Vasudevan K. Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque: A Preliminary Observation. Cureus 2020;12(1):e6809.
- Walsh JH, Maddison KJ, Rankin T, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep 2021;44(11):zsab149.
- Saleska JL, Bryant C, Kolobaric A, et al. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. J Am Nutr Assoc 2023.
- Bonn-Miller MO, Feldner MT, Bynion TM, Eglit GML, Brunstetter M, Kalaba M, Zvorsky I, Peters EN, Hennesy M. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Exp Clin Psychopharmacol. 2023.
- Moore CF, Weerts EM, Kulpa J, et al. Pharmacokinetics of Oral Minor Cannabinoids in Blood and Brain. Cannabis Cannabinoid Res 2023;8(S1):S51-S61.
- Gojani EG, Wang B, Li DP, Kovalchuk O, Kovalchuk I. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. Molecules 2023;28(18):6487.
- Arnold JC, Occelli Hanbury-Brown CV, Anderson LL, et al. A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats. Neuropsychopharmacology 2024.
- Anderson LL, Hawkins NA, Yip KL, Udoh M, Kearney JA, Arnold JC. Preclinical Evidence for a Drug-Drug Interaction Between Cannabinol and Melatonin. Basic Clin Pharmacol Toxicol 2025;136(1):e14120.
- Voorde WT, Wind S, Abdisalaam I, et al. A suction blister model to characterize epidermal wound healing and evaluate the efficacy of the topical wound healing agent INM-755 in healthy volunteers. Eur J Pharm Sci 2025;204:106867.